Temelimab

Temelimab is an experimental drug currently under investigation for the treatment of multiple sclerosis (MS). It is being developed by GeNeuro, a Swiss pharmaceutical company.

Mechanism of Action

Temelimab is a humanized monoclonal antibody that targets a protein called pHERV-W Env, which is thought to play a key role in the pathogenesis of MS. The drug is designed to neutralize the protein, thereby reducing inflammation and preventing the progression of the disease.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of temelimab in patients with MS. In a Phase 2b trial, the drug demonstrated a good safety profile and showed potential benefits in reducing brain atrophy and improving physical function. However, further research is needed to confirm these findings.

Potential Benefits

If successful, temelimab could offer a new treatment option for patients with MS, a chronic and often disabling disease that affects the central nervous system. The drug could potentially slow the progression of the disease and improve quality of life for patients.

See Also

• Multiple sclerosis
• Monoclonal antibodies
• Clinical trials
• GeNeuro

References

<references />

   This article is a medical stub. You can help WikiMD by expanding it!